Can J&J score sales with FDA’s new Olysio-plus-Sovaldi approval?

Tracy Staton

Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. The question now is how much that will help Olysio withstand competition, both current and forthcoming.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS